TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30548235

Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Smoking for more than 0 pack-years
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: N3 disease
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: T4 disease
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Negative p16 status
Number of subjects: 547
Study: 30548438

Group type: EXPERIMENTAL
Intervention: AVXS-101 gene replacement therapy
Number of subjects: 12
Study: 30549051

Group type: EXPERIMENTAL
Intervention: Epistaxis patients (n=41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Matched controls (n=41)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Study population (n=82)
Number of subjects: 82
Study: 30549418

Group type: EXPERIMENTAL
Intervention: Bilateral pelvic nerve crush injury (BPNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study: 30549425

Group type: EXPERIMENTAL
Intervention: Serum anti-cardiac myosin (CM) antibody detected at transplantation and at 12 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma VEGF-A levels pretransplant
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma VEGF-C levels pretransplant
Number of subjects: 200

Group type: COMPARATOR
Intervention: Early intravascular ultrasound findings or other candidate biomarkers
Number of subjects: 200
Study: 30550345

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 0
Study: 30551012

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 30551202

Group type: EXPERIMENTAL
Intervention: Carbonic anhydrase inhibitor (CAI) treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: No treatment (natural history)
Number of subjects: 56
Study: 30551910

Group type: EXPERIMENTAL
Intervention: ABC pathway (A: Time in Therapeutic Range ≥65%; B: EHRA symptom scale I-II; C: optimized cardiovascular comorbidity management)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Symptomatic patients (EHRA III-IV)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Optimally managed patients in the ABC group (n=198)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Multivariate Cox proportional regression analysis
Number of subjects: 907
Study: 30552056

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir
Number of subjects: 300
Study: 30552109

Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide knockdown (ASO-KD) of nicotinamide
Number of subjects: 0
Study: 30552130

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) with autoantibodies (AAB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) without autoantibodies (AAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30552129

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30552135

Group type: EXPERIMENTAL
Intervention: Recent-onset type 1 diabetes (T1D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (without diabetes)
Number of subjects: 0
Study: 30552156

Group type: EXPERIMENTAL
Intervention: Vinflunine plus sorafenib
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vinflunine 280 mg/m2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vinflunine 320 mg/m2
Number of subjects: 22
Study: 30552511

Group type: EXPERIMENTAL
Intervention: TAVI with SAPIEN 3 transcatheter heart valves
Number of subjects: 235
Study: 30552626

Group type: EXPERIMENTAL
Intervention: Standardized triage protocol
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Triage process
Number of subjects: 776
Study: 30553878

Group type: EXPERIMENTAL
Intervention: Home food availability of healthful foods (fruits, vegetables, meats)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Home food availability of unhealthful foods (sugar-sweetened beverages)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Overall dietary intake recommendations
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Accessibility and purchasing frequency of foods
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Home food environments (HFE)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Recommendations to improve dietary intake quality
Number of subjects: 164
Study: 30554141

Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GDF-15 levels <564 pg/L
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TAK1 inhibition with 5(Z)-7-oxozeaenol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 30
Study: 30554418

Group type: EXPERIMENTAL
Intervention: InnFocus MicroShunt
Number of subjects: 889

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 889
Study: 30554548

Group type: EXPERIMENTAL
Intervention: Obesity measured by body mass index (BMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity measured by another unspecified measure
Number of subjects: 0
Study: 30554571

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate therapy
Number of subjects: 1303
Study: 30554975

Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing information needs and barriers to colorectal cancer screening
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing preferences for information delivery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing fears and concerns regarding colonoscopy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient focus groups discussing the use of patient portals
Number of subjects: 45
Study: 30555051

Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen.
Number of subjects: 55
Study: 30555048

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and Velpatasvir (100 mg) tablet once daily for 12 weeks
Number of subjects: 375
Study: 30555280

Group type: EXPERIMENTAL
Intervention: Repetitive administration of intravenous levosimendan after discharge from an acute episode of worsening heart failure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy for advanced heart failure.
Number of subjects: 0
Study: 30555384

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy modules
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Positive psychology modules
Number of subjects: 103
Study: 30555714

Group type: EXPERIMENTAL
Intervention: Lumbar Spinal Manipulative Therapy (SMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 40
Study: 30555800

Group type: EXPERIMENTAL
Intervention: Piver Type II Hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piver Type III Hysterectomy
Number of subjects: 0
Study: 30542662

Group type: EXPERIMENTAL
Intervention: Screening and care interventions for tuberculosis and HIV
Number of subjects: 0
Study: 30556053

Group type: EXPERIMENTAL
Intervention: Multimedia intervention (website + booklet)
Number of subjects: 552
Study: 30556172

Group type: EXPERIMENTAL
Intervention: Criticism as a management strategy
Number of subjects: 256
Study: 30556332

Group type: EXPERIMENTAL
Intervention: Testosterone (T)/Nestorone (NES) combination gel applied by men (62 mg/8 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Shirt covering the application site
Number of subjects: 24

Group type: COMPARATOR
Intervention: Showering before contact
Number of subjects: 24
Study: 30556457

Group type: EXPERIMENTAL
Intervention: Properly sized nasotracheal tubes (sizes 6.0-8.0)
Number of subjects: 40
Study: 30542662

Group type: EXPERIMENTAL
Intervention: Optimised screening, prevention and care for tuberculosis and HIV
Number of subjects: 0
Study: 30556630

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 30557448

Group type: EXPERIMENTAL
Intervention: Admission PTX3 levels
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: PTX3 combined with CURB-65
Number of subjects: 188
Study: 30557521

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 475
Study: 30557741

Group type: EXPERIMENTAL
Intervention: Wireless Motility Capsule (WMC)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Gastric Emptying Scintigraphy (GES)
Number of subjects: 167
Study: 30558502

Group type: EXPERIMENTAL
Intervention: Cardiac positron emission tomography studies with 4-[
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planar scintigraphy or positron emission tomography
Number of subjects: 0
Study: 30558581

Group type: EXPERIMENTAL
Intervention: RealRisks decision aid
Number of subjects: 40
Study: 30558613

Group type: EXPERIMENTAL
Intervention: Eating breakfast daily throughout childhood
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Daily family dinner
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Eating fast food less than once per week throughout childhood
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Eating meals while watching television <1/week throughout childhood
Number of subjects: 995
Study: 30558909

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week if required) for up to 7 years
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 11
Study: 30558987

Group type: EXPERIMENTAL
Intervention: Umbralisib (800 mg once daily) plus Ibrutinib (420 mg for CLL, 560 mg for MCL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Umbralisib plus Ibrutinib
Number of subjects: 44
Study: 30559136

Group type: EXPERIMENTAL
Intervention: Afabicin (Debio 1450, AFN-1720)
Number of subjects: 0
Study: 30559420

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of an antisense oligonucleotide to restore correct splicing
Number of subjects: 10
Study: 30559424

Group type: EXPERIMENTAL
Intervention: AZD5991
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD5991 in combination with bortezomib or venetoclax
Number of subjects: 0
Study: 30559603

Group type: EXPERIMENTAL
Intervention: PRO-SELF© Plus Pain Control Program (PCP), 6-week intervention, weekly psychoeducational sessions
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study: 30559966

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Physical Exercise and Dietary Therapy (PED-t)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both CBT and PED-t
Number of subjects: 187
Study: 30561229

Group type: EXPERIMENTAL
Intervention: SB5 administered via prefilled syringe (PFS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SB5 administered via autoinjector (AI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall impression of PFS and AI
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall preference for AI
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 49
Study: 30561271

Group type: EXPERIMENTAL
Intervention: Migraine history
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: SCAD patients with migraine
Number of subjects: 585

Group type: COMPARATOR
Intervention: SCAD patients without migraine
Number of subjects: 585
Study: 30561367

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR in LAD
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR in non-LAD
Number of subjects: 835
Study: 30561563

Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal hypergammaglobulinemia
Number of subjects: 0
Study: 30562118

Group type: EXPERIMENTAL
Intervention: Whole-blood transcriptome profiling
Number of subjects: 0
Study: 30562390

Group type: EXPERIMENTAL
Intervention: Preconception anemia (hemoglobin <12 g/dL)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Iron deficiency among anemic cases
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Malaria infection at enrolment
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Inflammation
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Increased mid-upper arm circumference
Number of subjects: 1248
Study: 30562587

Group type: EXPERIMENTAL
Intervention: CMVPepVax (two injections at days 28 and 56 post-HCT)
Number of subjects: 0
Study: 30563388

Group type: EXPERIMENTAL
Intervention: EmboTrap
Number of subjects: 40
Study: 30563576

Group type: EXPERIMENTAL
Intervention: Centrilobular emphysema
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Systemic inflammation markers
Number of subjects: 300
Study: 30563754

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT)
Number of subjects: 18
Study: 30563818

Group type: EXPERIMENTAL
Intervention: P3 (Prepared, Protected, emPowered) mobile app intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P3+ mobile app intervention with adherence counseling via SMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 30563875

Group type: EXPERIMENTAL
Intervention: Midostaurin added to chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin as single-agent maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 30563931

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day)
Number of subjects: 84
Study: 30564163

Group type: EXPERIMENTAL
Intervention: Advance Care Planning intervention in nursing homes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 30564373

Group type: EXPERIMENTAL
Intervention: QRISK2
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: JBS3 'heart age'
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: hsCRP levels
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Statin therapy eligibility
Number of subjects: 673
Study: 30564436

Group type: EXPERIMENTAL
Intervention: Standard of care plus exercise-based cardiac rehabilitation (CR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 27
Study: 30564451

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 30564993

Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) method for golimumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Induction regimen of golimumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: User-friendliness evaluation via questionnaire
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mucosal healing evaluation at week 14
Number of subjects: 10
Study: 30565055

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention to reduce postprandial glucose (PPG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 37
Study: 30565371

Group type: EXPERIMENTAL
Intervention: COMBO stent treatment
Number of subjects: 1000
Study: 30566600

Group type: EXPERIMENTAL
Intervention: Severe malaria patients
Number of subjects: 107

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 107
Study: 30566616

Group type: EXPERIMENTAL
Intervention: Cancer survivors (170 participants)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Similar-aged controls (135 participants)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Late reproductive-aged controls (71 participants)
Number of subjects: 376
Study: 30566661

Group type: EXPERIMENTAL
Intervention: STand Up Frequently From Stroke (STUFFS) program, an 8-week home-based sedentary behavior change intervention
Number of subjects: 25
Study: 30567529

Group type: EXPERIMENTAL
Intervention: HDIL-2 + MAGE-A3 CI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maintenance MAGE-A3 CI monotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: HDIL-2 alone
Number of subjects: 18
Study: 30567548

Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 78
Study: 30567584

Group type: EXPERIMENTAL
Intervention: Diffuse Reflectance Spectroscopy (DRS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous mode DRS measurements
Number of subjects: 27
Study: 30568035

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study: 30568582

Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral monitoring
Number of subjects: 0
Study: 30568870

Group type: EXPERIMENTAL
Intervention: Direct notification of cervical cytology results by the pathology department
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conveying results via the general practitioner (usual care)
Number of subjects: 0
Study: 30569031

Group type: EXPERIMENTAL
Intervention: Meat-rich diet (84% in severe AP)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Mild/moderate diet (72% in mild AP, 67% in moderate AP)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Dietary habits overall
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Persistent organ failure association
Number of subjects: 407
Study: 30569038

Group type: EXPERIMENTAL
Intervention: Novel nano-iron supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30569586

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales-II (VABS-II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician Global Impression (CGI) scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VABS-II and CGI scale
Number of subjects: 0
Study: 30569759

Group type: EXPERIMENTAL
Intervention: Fluocinolone intravitreal implant (ILUVIEN)
Number of subjects: 0
Study: 30570077

Group type: EXPERIMENTAL
Intervention: Instituto Butantan seasonal trivalent influenza vaccine (TIV)
Number of subjects: 1253
Study: 30570273

Group type: EXPERIMENTAL
Intervention: Cigarette demand and delay discounting (DD)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Cigarette consumption assessment
Number of subjects: 277
Study: 30570315

Group type: EXPERIMENTAL
Intervention: low-intensity mindfulness training
Number of subjects: 125

Group type: COMPARATOR
Intervention: control group (not specified)
Number of subjects: 125
Study: 30570358

Group type: EXPERIMENTAL
Intervention: Subcutaneous Echogenicity Grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous Echo-Free Space Grade
Number of subjects: 0
Study: 30570502

Group type: EXPERIMENTAL
Intervention: Surgical treatment for POP
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Preoperative assessments (PFDI-20, PFIQ-7)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Severity Scale
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Postoperative assessments (PFDI-20, PFIQ-7, PROMIS-57)
Number of subjects: 103
Study: 30570526

Group type: EXPERIMENTAL
Intervention: Nadir CD4 T-cell count
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: ANA
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: aSMA
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: aLKM1
Number of subjects: 223
Study: 30570649

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg administered intravenously every 3 weeks until disease progression, unacceptable toxic effects, or study withdrawal, for up to 2 years.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with ESCC.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with adenocarcinoma.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with PD-L1-positive tumors.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with PD-L1-negative tumors.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pembrolizumab treatment-related adverse events.
Number of subjects: 121
Study: 30570744

Group type: EXPERIMENTAL
Intervention: Mocetinostat (70 mg 3 times per week escalating to 90 mg TIW)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mocetinostat
Number of subjects: 17
Study: 30570763

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab (600 mg maintenance dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab (1200 mg loading dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab and trastuzumab (fixed-dose combination)
Number of subjects: 0
Study: 30571184

Group type: EXPERIMENTAL
Intervention: 1 ng/kg lipopolysaccharide (LPS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Knockdown experiments in THP-1 monocytes
Number of subjects: 40
Study: 30571191

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1175
Study: 30571194

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk score
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: EuroSCORE-2 (ES2)
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Contemporary Cohort (CC)
Number of subjects: 2060

Group type: COMPARATOR
Intervention: STICH cohort
Number of subjects: 2060
Study: 30571197

Group type: EXPERIMENTAL
Intervention: HFpEF (EF ≥45%)
Number of subjects: 202

Group type: COMPARATOR
Intervention: HFrEF (EF <45%)
Number of subjects: 202
Study: 30571200

Group type: EXPERIMENTAL
Intervention: Melody valve implantation
Number of subjects: 68
Study: 30571203

Group type: EXPERIMENTAL
Intervention: Post chronic total occlusion PCI
Number of subjects: 26

Group type: COMPARATOR
Intervention: Subintimal recanalization
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intrapaque recanalization
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4 months follow-up
Number of subjects: 26